A multicenter study on clinical efficacy of ofloxacin in respiratory and urinary tract infections.

A multicenter trial on the efficacy and tolerability of ofloxacin in upper and lower respiratory tract infections and urinary tract infections was carried out on 1,436 patients (926 males and 510 females; mean age 55.9 +/- 18.4 years). Three dosage regimens were randomly applied: 200 mg, 300 mg and 400 mg ofloxacin b.i.d. by the oral route. The overall clinical outcome expressed as the ratio of the number of patients cured and improved to the number of patients treated was 279/324 (86%) in upper respiratory tract infections; 612/667 (91.8%) in lower respiratory tract infections and 418/445 (93.9%) in urinary tract infections. Out of 872 bacterial strains isolated in 802 patients, 742 (85.1%) were eradicated. Side effects not requiring interruption of therapy were observed in 65 patients (4.5%), while interruption was necessary in 23 patients (1.6%). The most frequent side effects were gastrointestinal disturbances. In conclusion ofloxacin showed a good clinical efficacy and tolerability in the treatment of respiratory and urinary tract infections.

RCT Entities:   Population Interventions Outcomes